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Introduction
A signiﬁ cant number of patients who undergo major 
surgery suﬀ er postoperative complications, many of 
which may be avoidable [1,2]. Th e associated health and 
ﬁ nancial loss is signiﬁ cant, especially considering 
patients who suﬀ er from postoperative complications 
suﬀ er long-term morbidity [3]. A signiﬁ cant proportion 
of patients undergoing surgery suﬀ er from postoperative 
complications, and identiﬁ cation of this cohort of 
patients may enable appropriate preventative measures 
to be taken [4]. Perioperative goal-directed therapy 
(GDT) aims to match the increased oxygen demand 
incurred during major surgery, by ﬂ ow-based haemo-
dynamic monitoring and therapeutic interventions to 
achieve a predetermined haemodynamic endpoint. 
When carried out early, in the right patient cohort, and 
with a clearly deﬁ ned protocol, GDT has been shown to 
reduce postoperative mortality and morbidity [5].
Despite this, postoperative GDT is not carried out 
widely, perhaps due to the lack of evidence for its beneﬁ t 
from large multicenter randomized clinical trials. 
Scepticism about GDT may exist for a number of reasons: 
many of the studies performed may be considered 
outdated; the high mortality rates in some of the studies 
performed are not representative of current clinical 
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practice; and pulmonary artery catheters (PACs) are used 
in many of the clinical trials but have been largely 
superseded by less invasive haemodynamic monitors. A 
recent meta-analysis has demonstrated that although 
studies prior to 2000 demonstrate a beneﬁ t in mortality, 
studies con ducted after 2000 demonstrate a signiﬁ cant 
reduction in complication rates [5]. Furthermore, the 
reduction in complication rates is signiﬁ cant regardless 
of the type of haemodynamic monitor used.
We hypothesized that the beneﬁ ts of GDT are greater 
in patients who are at higher risk of mortality. We deﬁ ned 
risk by the mortality rate of the study population 
undergoing major surgery. We conducted this meta-
analysis to determine if GDT in high-risk surgical 
patients undergoing major non-cardiac surgery improves 
postoperative mortality and morbidity, and if this was 
aﬀ ected by the mortality risk among the population 
studied.
Methods
Eligibility criteria
We reported only randomized controlled trials, that 
reported morbidity (complications) and mortality as 
primary or secondary outcomes. GDT was deﬁ ned as the 
term encompassing the use of haemodynamic monitoring 
and therapies aimed at manipulating haemodynamics 
during the perioperative period to achieve a predeter-
mined haemodynamic endpoint(s). Studies with GDT 
started pre-emptively in the perioperative period 
(24  hours before, intraoperative or immediately after 
surgery) were included. Th e GDT must have an explicit 
protocol, deﬁ ned as detailed step-by-step instructions for 
the clinician based on patient-speciﬁ c haemodynamic 
data obtained from a haemodynamic monitor or surro-
gates (for example, lactate, oxygen extraction ratio), and 
predeﬁ ned interventions carried out by the clinician in 
an attempt to achieve the goal(s). Interventions included 
ﬂ uid administration alone or ﬂ uids and inotropes 
together. As the use of inotropic agents was aimed at a 
speciﬁ c haemodynamic goal(s) and titrated accordingly, 
ﬁ xed dose studies of inotropes were excluded. Only 
studies involving adult general surgical populations were 
included, and studies involving cardiac, trauma and 
paediatric surgery were excluded.
Information sources
A systematic literature search of MEDLINE (via Ovid), 
EMBASE (via Ovid) and the Cochrane Controlled 
Clinical trials register (CENTRAL, issue 4 of 2012) was 
conducted to identify suitable studies. Only articles 
written in English were considered. Date restrictions 
were not applied to the CENTRAL and MEDLINE 
searches. EMBASE was restricted to the years 2009 to 
2012 [6]. Th e last search update was in April 2012.
Search strategy
We included the following search terms: goal-directed 
therapy, optimization, haemodynamic, goal oriented, 
goal targeted, cardiac output, cardiac index, oxygen 
delivery, oxygen consumption, cardiac volume, stroke 
volume, ﬂ uid therapy, ﬂ uid loading, ﬂ uid administration, 
optimization, supranormal, lactate and extraction ratio. 
Search terms were entered into the electronic databases 
using search strategy methods validated by the Cochrane 
collaboration (see Box 1 for search strategies used) [7]. In 
addition to searching electronic databases, previous 
review articles on the subject were hand-searched for 
further references.
Methodological quality of included studies
Methodological quality of included studies was assessed 
using criteria described by Jadad and colleagues [8]. Th e 
Jadad scale analyzes methods used for random assignment, 
blinding and ﬂ ow of patients in clinical trials. Th e range of 
possible scores is 0 (lowest quality) to 5 (highest quality). 
Studies were not excluded based on Jadad scores.
Analysis of outcomes
Th ree investigators independently screened both the 
titles and abstracts to exclude non-pertinent studies. 
Relevant full text articles were then retrieved and 
analysed for eligibility against the pre-deﬁ ned inclusion 
criteria. Information from selected studies was extracted 
using a standardized data collection form. Data were 
collected independently by three diﬀ erent investigators 
(GA, NA and CC) and discrepancies resolved by a fourth 
author (MC).
Hospital mortality was reported in all the included 
articles and was the primary outcome of our study. 
Morbidity, expressed as number of patients with compli-
cations, was the secondary outcome. Mortality risk 
groups were based on the deﬁ nition of the high-risk 
surgical patient by Boyd and Jackson, such that patients 
whose risk of mortality was 5 to 19% and ≥20% were 
classiﬁ ed as high-risk and extremely high-risk, respect-
ively [9]. We therefore performed subgroup analyses 
based on the control group mortality in each study. We 
created three subgroups based on the mortality rate of 
the control group. Mortality rates of 0 to 4.9%, 5 to 19.9%, 
and ≥20% were considered intermediate, high risk, and 
extremely high risk, respectively. Mortality and compli-
ca tions were analyzed according to the above subgroups. 
Studies were also analyzed according to the type of 
monitor used, type of interventions, the therapeutic 
goals, and the use of ‘supranormal’ physiological goals.
Statistical analysis
Dichotomous data outcomes were analysed using the 
Mantel-Haenszel random eﬀ ects model and results 
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Box 1. Search strategies 
1.  MEDLINE database (OVID interface): the Cochrane highly 
sensitive search strategy was used: 
#1.  randomized Controlled Trials as Topic/
#2.  randomized controlled trial/
#3.  random Allocation/
#4.  double Blind Method/
#5.  single Blind Method/
#6.  clinical trial/
#7.  controlled clinical trial.pt.
#8.  randomized controlled trial.pt.
#9.  multicenter study.pt.
#10.  clinical trial.pt.
#11.  exp Clinical Trials as topic/
#12.  or/1-11
#13.  (clinical adj trial$).tw.
#14.  ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw.
#15.  randomly allocated.tw.
#16.  (allocated adj2 random$).tw.
#17.  or/13-16
#18.  12 or 17
#19.  case report.tw.
#20.  letter/
#21.  historical article/
#22.  or/19-21
#23.  18 not 22
#24.  exp surgery/
#25.  surgery.tw.
#26.  surgery.mp.
#27.  24 or 25 or 26
#28.  exp goal directed/ or goal directed.tw. or goal directed.mp.
#29.  exp goal oriented/ or goal oriented.tw. or goal oriented.mp.
#30.  exp goal target/ or goal target.tw. or goal target.mp.
#31.  exp cardiac output/ or cardiac output.tw. or cardiac output.mp.
#32.  exp cardiac index/ or cardiac index.tw. or cardiac index.mp.
#33.  exp oxygen delivery/ or oxygen delivery.tw. or oxygen delivery.mp.
#34.  exp oxygen consumption/ or oxygen consumption.tw. or oxygen 
consumption.mp
#35.  exp cardiac volume/ or cardiac volume.tw. or cardiac volume.mp.
#36.  exp stroke volume/ or stroke volume.tw. or stroke volume.mp.
#37.  exp fl uid therapy/ or fl uid therapy.tw. or fl uid therapy.mp.
#38.  exp fl uid loading/ or fl uid loading.tw. or fl uid loading.mp.
#39.  exp fl uid administration/ or fl uid administration.tw. or fl uid administration.
mp.
#40.  exp optimization/ or optimization.tw. or optimization.mp.
#41.  exp optimisation/ or optimisation.tw. or optimisation.mp.
#42.  exp supranormal/ or supranormal.tw. or supranormal.mp.
#43.  exp lactate/ or lactate.tw. or lactate.mp.
#44.  exp extraction ratio/ or extraction ratio.tw. or extraction ratio.mp.
#45.  #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or 
#39 or #0 or #41or  #42 or #43 or #44
#46.  #23 and #27 and #45
2.  Embase (OVID interface):  search restricted  to the years 
2009 to 2012: 
#1.  Clinical trial/
#2.  Randomized controlled trial/
#3.  Randomization/
#4.  Single blind procedure/
#5.  Double blind procedure/
#6.  Crossover procedure/
#7.  Placebo/
#8.  Randomi?ed controlled trial$.tw.
#9.  Rct.tw.
#10.  Random allocation.tw.
#11.  Random allocated.tw
#12.  Allocated randomly.tw.
#13.  (allocated adj2 random).tw.
#14.  Single blind$.tw.
#15.  Double blind$.tw.
#16.  Placebo$.tw
#17.  Prospective study/
#18.  Or/1-17
#19.  Case study/
#20.  Case report.tw.
#21.  Abstract report/or letter/
#22.  Or/19-21
#23.  18 not 22 
#24.  surgery 
#25.  exp surgery/or surgery
#26.  surg$
#27.  24 or 25 or 26 
#28.  exp heart/ or heart.mp.) and output.mp.
#29.  exp heart output/ or heart output.mp.
#30.  goal directed
#31.  goal oriented 
#32.  goal target
#33.  exp heart index/ or heart index.mp.
#34.  exp heart stroke volume/ or heart stroke volume.mp.
#35.  exp oxygen consumption/ or oxygen consumption.mp.
#36.  oxygen delivery.mp.
#37.  exp fl uid therapy/
#38.  fl uid administration.mp
#39.  fl uid loading.mp.
#40.  hemodynamic.mp
#41.  supranormal.mp.
#42.  optimisation.mp.
#43.  optimization.mp.
#44.  exp lactate/
#45.  extraction ratio.mp
#46.  #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or 
#39 or #40 or #41 or #42  or #43 or #44 or #45
#47.  #23 and #27 and #46
3.  Cochrane clinical trials database (CENTRAL):
#1.  surgery in Trials
#2.  surgical* in Trials 
#3.  surgery* in Trials 
#4.  #1 OR #2 OR #3 
#5.  cardiac near output* in trials
#6.  cardiac near volume* in Trials 
#7.  cardiac near index* in Trials 
#8.  oxygen near delivery* in Trials 
#9.  oxygen near consumption* in Trials 
#10.  supranormal* in Trials 
#11.  stroke near volume* in Trials 
#12.  fl uid near therapy* in Trials
#13.  fl uid near administration* in Trials 
#14.  fl uid near loading* in Trials 
#15.  extraction near ratio* in Trials 
#16.  lactate* in Trials 
#17.  goal near directed* in Trials *
#18.  goal near oriented* in Trials 
#19.  goal near target* in Trials 
#20.  Hemodynamic near optimization* in trials
#21.  Haemodynamic near optimization * in trials 
#22.  Optimization* in trials 
#23.  Optimisation* in trials 
#24.  #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23
#25.  #4 AND#24
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presented as an odds ratio (OR) with 95% conﬁ dence 
intervals (CI). Th e meta-analysis was carried out using 
review manager (‘Revman’) for MAC (version 5.1, 
Cochrane collaboration, Oxford, UK). Statistical hetero-
geneity was assessed using the I2 methodology. When an 
I2 value of >50% was present heterogeneity and incon-
sistency were considered signiﬁ cant, and when it was 
>75% these were considered highly signiﬁ cant [10]. All 
P-values were two-tailed and considered statistically 
signiﬁ cant if <0.05.
Results
Included trials
Th e search strategy used in this study produced 12,938 
potential titles (Figure  1). After screening of titles and 
abstracts, 307 references were identiﬁ ed as relevant to 
perioperative GDT. After further screening of titles and 
abstracts against our inclusion criteria, 85 references 
were retrieved for full text analysis. Detailed full text 
evaluation excluded 13 studies, as they were not random-
ized controlled trials [11-23]. Analysis of the remaining 
72 randomized controlled trials produced the following 
exclusions: studies focusing on ﬂ uid management 
strategies (that is, liberal versus restrictive) [24-33], use 
of ‘ﬁ xed dose’ inotropic agents not titrated to a pre-
determined goal [34-38], cardiac surgery [39-44], trauma 
[45-52], paediatric surgery [53] and critically ill medical 
populations [54-62]. A study not using protocols to direct 
application of GDT was also excluded [63]. Th e quality of 
the trials was analysed using the Jadad score. Th e median 
Jadad score was 3.
Description of studies
A total of 32 studies were included in the meta-analysis 
(Table  1) [64-95]. Th ese 32 studies included a total of 
2,808 patients, 1,438 in the GDT arm and 1,370 in the 
control treatment arm. Five studies included patients 
who were considered extremely high risk, 12 included 
patients who were high risk, and 15 included patients 
who were intermediate risk. Th e intermediate-risk, high-
risk, and extremely high-risk mortality subgroups 
included 1,569, 924, and 315 patients, respectively. Th ere 
were similar numbers of patients in the GDT and control 
arms. Twenty studies initiated GDT at start of surgery, 
whilst the other studies initiated GDT before or imme-
diately after surgery.
Mortality
Th ree studies did not report any deaths in the control or 
intervention group. All 32 studies included mortality 
rates (Figure 2). Although there was an overall beneﬁ t on 
mortality (OR 0.52, 95% CI 0.36 to 0.74; P  =  0.003), 
subgroup analyses revealed that mortality beneﬁ t was 
seen only in studies that included extremely high risk 
patients (OR 0.20, 95% CI 0.09 to 0.41; P  <  0.0001) but 
not for the intermediate-risk patients (OR 0.83, 95% CI 
0.41 to 1.69; P  =  0.62). Th ere was a trend towards a 
reduction in mortality in the high risk group (OR 0.65, 
95% CI 0.39 to 1.07; P = 0.09; Figure 2). Further subgroup 
analyses of mortality as an endpoint revealed that 
mortality was reduced in the studies using a pulmonary 
artery catheter (OR 0.3, 95% CI 0.15 to 0.60; P = 0.0007), 
ﬂ uids and inotropes as opposed to ﬂ uids alone (OR 0.41, 
95% CI 0.23 to 0.73; P = 0.002), cardiac index or oxygen 
delivery index as a goal (OR 0.36, 95% CI 0.21 to 0.36; 
P = 0.0003), and a supranormal resuscitation target (OR 
0.27, 95% CI 0.15 to 0.47; P < 0.00001) (Table 2).
Morbidity
Twenty-seven studies (including 2,477 patients) reported 
the number of patients with postoperative complications. 
Meta-analysis of these studies revealed an overall 
signiﬁ cant reduction in complication rates (OR 0.45, 95% 
CI 0.34 to 0.60; P  <  0.00001; Figure  3). Consistent with 
the mortality beneﬁ ts, the reduction in morbidity was 
greatest in the extremely high-risk group (OR 0.27, 95% 
CI 0.15 to 0.51; P  <  0.0001). However, there was also a 
signiﬁ cant morbidity beneﬁ t in the intermediate risk 
group (OR 0.43, 95% CI 0.27 to 0.67; P = 0.0002) and the 
high-risk groups (OR 0.56, 95% CI 0.36 to 0.89; P = 0.01) 
(Figure  3). Th e reduction in the number of patients 
suﬀ ering postoperative complications was seen across all 
subgroups, apart from studies that did not use the oxygen 
delivery index (DO2I; ml/minute/m2), the cardiac index 
(CI; ml/minute/m2), stroke volume (SV; ml), or corrected 
ﬂ ow time (FTc) as a goal (OR 0.48, 95% CI 0.22 to 1.04; 
P = 0.06), although this approached statistical signiﬁ cance 
(Table 3).
Discussion
We believe that GDT in high-risk surgical patients is 
likely to have the greatest beneﬁ t if carried out early, in 
the right patient cohort and with a clearly deﬁ ned 
protocol. We performed this meta-analysis to test the 
hypothesis that patients with the highest perioperative 
risk gain the greatest beneﬁ ts from GDT. Studies without 
clearly deﬁ ned GDT protocols and studies that initiated 
GDT late in the postoperative course were therefore 
excluded from our meta-analysis. Studies were stratiﬁ ed 
into diﬀ erent risk groups based on the mortality rate of 
the control group in the study. Heterogeneity in the year 
of study, patient demographics, type and urgency of 
surgery, and health care facilities among the diﬀ erent 
studies are likely to account for the diﬀ erence in mortality 
rates.
A reduction in mortality associated with GDT was seen 
only in the extremely high-risk group of patients (baseline 
mortality rate of >20%). A baseline mortality rate of >20% 
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is unusual in current practice [4,96]; in this sense it is 
interesting to note that two of ﬁ ve studies with a baseline 
mortality rate of >20% were carried out within the past 
decade. Neither of these studies demonstrated a survival 
beneﬁ t with GDT [80,97]. One of these studies demon-
strated a reduction in complication rates [97], whilst the 
other demonstrated a trend towards a reduction in 
complication rates [80].
Supranormal physiological targets, targeting DO2I or 
CI, the use of inotropes in addition to ﬂ uids, and the use 
of a PAC were also associated with an improvement in 
survival. As ﬁ rst demonstrated by Shoemaker and 
colleagues [19], a supra normal physiological target of 
global oxygen delivery to ameliorate the oxygen deﬁ cit 
incurred during major surgery is associated with a 
survival beneﬁ t. Th is is likely to explain the other 
associations with an improve ment in morbidity across all 
risk groups. Th e combination of ﬂ uids and inotropes is 
more likely to achieve a supranormal physiological target, 
as opposed to ﬂ uids alone. All eight studies using the 
oesophageal doppler used ﬂ uids alone, reﬂ ected by the 
lack of mortality beneﬁ t with the use of FTc or SV as a 
target. Th e survival beneﬁ t associated with the use of 
PACs is unlikely to be due to the use of the PACs per se. 
Th e survival beneﬁ t associated with PAC use may be 
explained by a number of factors. Th ese include the 
ability to measure and there fore achieve supranormal 
DO2I, and the use of inotropes in addition to ﬂ uids in all 
studies using a PAC.
Th e reduction in the number of patients suﬀ ering post-
operative complications was seen across all sub groups, 
apart from studies that did not use DO2I, CI, SV, or FTc 
as a goal. However, there was a trend towards fewer 
complications among the GDT cohort in these studies. 
Goals used by these studies included lactate, pulse 
pressure variation, plethysmographic variability index, 
Figure 1. Flow diagram illustrating search strategy. RCT, randomised controlled trial.
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pulmonary artery occlusion pressure, oxygen extraction 
ratio, and intrathoracic blood volume [73,74,76,80, 87, 
93,95]. Consistent with the trends seen with mortality, 
the reduction in complication rates was most profound in 
the extremely high-risk group of patients, protocols with 
supranormal physiological targets, targeting DO2I or CI, 
and the use of inotropes in addition to ﬂ uids. In contrast 
to the beneﬁ ts seen in mortality, however, the subgroup 
Figure 2. Eff ect of goal-directed therapy (GDT) in protocol group versus control group on mortality rate, grouped by control group 
mortality rates. CI, confi dence interval; M-H, Mantel-Haenszel.
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using the ‘other cardiac output monitors’ had a greater 
reduction in complication rate than the subgroup using 
the PAC. Th is may relate to the complexity and invasive 
nature of the PAC in comparison to less invasive cardiac 
output monitors [98-100].
Th ere remains signiﬁ cant heterogeneity in complication 
rates among postoperative patients in diﬀ erent centres 
[4,96]. Although diﬀ erences in patient demographics are 
not modiﬁ able, optimal management of the high-risk 
surgical patient during the perioperative phase may 
improve overall outcomes. Despite a requirement for an 
increase in healthcare resources to oﬀ er early GDT to 
high-risk surgical patients, reductions in immediate post- 
operative complications translate to overall beneﬁ ts in 
healthcare costs. Any perceived increase in resource allo-
cation results in a lower patient mortality and morbidity, 
and therefore a ﬁ nancial saving [101]. Furthermore, 
reduc tion in immediate postoperative complications has 
far-reaching eﬀ ects, with a potential beneﬁ cial eﬀ ect on 
long-term survival [102].
This meta-analysis includes trials from 1988 to 2011. 
As surgical techniques, perioperative care, and patient 
selection have been refined over these years, the 
overall mortality of patients has reduced. As such, the 
applica bility of historical trials to current day practice 
may not be valid. This has recently been evaluated in a 
meta-analysis of 29 perioperative GDT trials carried out 
between 1995 and 2008 [5]. Th ere was an approximate 
halving of mortality rates in the control group every 
decade (29.5%, 13.5%, 7%). Despite a reduction in mortality 
rate, the morbidity rate remained constant, with approxi-
mately a third of patients experiencing post operative 
complications. Perioperative GDT should there fore oﬀ er a 
reduction in complication rates in current practice.
We acknowledge that there is an element of subjectivity 
in our decision to include trials in this meta-analysis. 
Many studies were conducted in single centres with 
limited patient numbers, and not all studies conducted 
were of a high quality design. Th is is reﬂ ected by the 
median Jadad score of 3. Th e eﬀ ect of study quality on 
outcomes of GDT trials has been analysed in a recent 
meta-analysis [5]. Most perioperative GDT trials were 
singe-centre studies, and only a few were conducted in a 
double-blind manner. In contrast to the lower quality 
studies, the higher quality studies (deﬁ ned as a Jadad 
score of at least 3) did not demonstrate any beneﬁ t in 
mortality reduction. However, the beneﬁ cial eﬀ ect of 
reduction in perioperative complication rates was evident 
irrespective of trial quality.
One of the main limitations of this study is the lack of 
data on the volume and type of ﬂ uids given, and the dose 
of inotropes used due to variation and inconsistencies in 
Table 2. Mortality by subgroup analysis
   Number of Mortality in Number of Mortality in   
  Number of patients in GDT patients in control   
  studies GDT group group (%) control group group (%) Odds ratio 95% CI P-value
Risk group        
 Intermediate risk 15 807 16 (2.0) 762 17 (2.2) 0.83 0.41-1.69 0.62
 High risk 12 489 31 (6.3) 435 45 (10.3) 0.65 0.39-1.07 0.09
 Extremely high risk 5 142 11 (7.7) 173 51 (29.5) 0.2 0.09-0.41 <0.0001
Fluid/inotropes        
 Fluid 16 732 25 (3.4) 738 38 (5.1) 0.72 0.42-1.23 0.23
 Fluid + inotrope 16 706 33 (4.7) 632 75 (11.9) 0.41 0.23-0.73 0.002
Goal        
 Supranormal 9 365 19 (5.2) 351 65 (18.5) 0.27 0.15-0.47 <0.00001
 Normal 23 1073 39 (3.6) 1,019 48 (4.7) 0.80 0.51-1.27 0.35
Target        
 CI/DO2I 15 674 30 (4.5) 592 73 (12.3) 0.36 0.21-0.36 0.0003
 FTc/SV 9 423 15 (3.5) 434 23 (5.3) 0.78 0.40-1.52 0.46
 Other 8 341 13 (3.8) 344 17 (4.9) 0.78 0.35-1.72 0.54
Type of monitor        
 PAC 11 494 20 (4.0) 445 62 (13.9) 0.3 0.15-0.6 0.0007
 ODM 8 378 10 (2.6) 389 17 (4.4) 0.77 0.35-1.69 0.51
 Other 13 566 28 (4.9) 536 34 (6.3) 0.74 0.43-1.28 0.28
CI, cardiac index (ml/minute/m2); DO2I, oxygen delivery index (ml/minute/m
2); FTc, corrected fl ow time; ODM, oesophageal doppler monitor; PAC, pulmonary artery 
catheter; SV, stroke volume (ml).
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reporting. However, it must be emphasised that the 
absolute volume of ﬂ uids used per se is not as important 
as the way in which ﬂ uid is given. Fluid therapy must be 
titrated against a patient’s response to a ﬂ uid challenge, 
with the use of haemodynamic monitoring [103]. Such 
‘goal-directed’ ﬂ uid therapy must also be given at the 
right time, as GDT is not beneﬁ cial after complications 
have already developed [104,105].
One of the other limitations is missing data on the 
number of patients with complications, due to variations 
in reporting of complications in the literature, with some 
studies reporting the number of complications as 
opposed to the number of patients with complications. 
Furthermore, we acknowledge that the deﬁ nitions and 
coding of complications are likely to vary between 
studies. We have analysed data extracted from studies, 
Figure 3. Eff ect of goal-directed therapy (GDT) in protocol group versus control group on the number of patients with complications, 
grouped by control group mortality rates. CI, confi dence interval; M-H, Mantel-Haenszel.
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rather than data of individual patients. As some of the 
studies included were carried out several years ago, 
obtaining data on individual patients would not have 
been possible. Despite these limitations, the results 
remain consistent across many subgroups of patients, 
and are consistent with other recent meta-analyses, 
supporting our hypothesis [5,106] and the recent EUSOS 
study which showed a mortality of 4% [107]. Th e beneﬁ t 
in terms of reduction of complications of GDT in the 
intermediate risk group may have implications for the 
majority of the European surgical population.
Conclusion
Despite heterogeneity in trial quality and design, early 
GDT among high-risk surgical patients has a signiﬁ cant 
beneﬁ t in reducing rates of complications. Th ere is also 
an associated reduction in mortality among patients at 
extremely high risk of perioperative death. GDT is of 
greatest beneﬁ t in patients with the highest risk of 
mortality.
Abbreviations
CI, cardiac index (ml/minute/m2); DO2I, oxygen delivery index (ml/minute/m
2); 
FTc, corrected fl ow time; GDT, goal-directed therapy; PAC, pulmonary artery 
catheter; SV, stroke volume (ml).
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Target        
 CI/DO2I 14 621 162 (26.1) 538 229 (42.6) 0.41 0.28-0.61 <0.0001
 FTc/SV 7 361 118 (32.7) 392 180 (45.9) 0.50 0.30-0.84 0.009
 Other 6 281 88 (31.3) 284 130 (45.8) 0.48 0.22-1.04 0.06
Type of monitor        
 PAC 10 441 99 (22.4) 391 129 (33.0) 0.49 0.30-0.80 0.005
 ODM 6 316 92 (29.1) 347 150 (43.2) 0.46 0.25-0.86 0.01
 Other 1! 506 177 (35.0) 476 260 (54.6) 0.41 0.26-0.64 0.0001
CI, cardiac index (ml/minute/m2); DO2I, oxygen delivery index (ml/minute/m
2); FTc, corrected fl ow time; ODM, oesophageal doppler monitor; PAC, pulmonary artery 
catheter; SV, stroke volume (ml).
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